Four-strata risk assessment in pulmonary arterial hypertension (PAH) patients treated with selexipag in real-world settings: Insights from EXPOSURE

Risk factors to guide pulmonary hypertension management

Chair(s): Athenais Boucly, Vasile Foris

Session type: Poster session

Tobias Lange

EVENTS HOME

Poster
Abstract

Previous presentation

Next presentation

Session content

The MRC Dyspnoea scale may predict survival in pulmonary arterial hypertension.

Folawemimo Arogundade

Poster

Abstract

Four-strata risk assessment in pulmonary arterial hypertension (PAH) patients treated with selexipag in real-world settings: Insights from EXPOSURE

Tobias Lange

Poster

Abstract

Have Physicians Learned Whats New in the 2022 ESC/ERS Pulmonary Hypertension Guidelines? Areas of Improvement and Areas of Further Education Need

Christy Rohani-montez

Poster

Abstract

Prognostic impact of pulmonary diffusing capacity for carbon monoxide in pulmonary hypertension

Milan Mohammad

Poster

Abstract

Biomarkers for diagnosis and disease severity in precapillary pulmonary hypertension.

Katarzyna Rososinska

Poster

Abstract

Clinical and economic burden of patients with PH-LD and PH-ILD in France

Vincent Cottin

Poster

Abstract

Concordance between physician and patient reported presence of symptoms in patients with pulmonary arterial hypertension in the US, Europe and Japan

Rogier Klok

Poster

Abstract

Phenotyping vasodilator responsiveness in idiopathic pulmonary arterial hypertension: any role for the cardiopulmonary exercise test?

Gayathiri Sivasubramaniam

Poster

Abstract

Higher circulating prolactin associates with lower mortality in pulmonary arterial hypertension

Wen-hui Wu

Abstract

Residual risk identified in routine non-invasive follow-up assessments in pulmonary arterial hypertension

Jonna Ostermann

Poster

Abstract

Biomarkers of angiogenesis in pulmonary arterial hypertension and pulmonary hypertension due to left heart diseases

Francesca Macera

Poster

Abstract

Follow-up of Calcium-Channel Blockers Responders and Risk Factors of Treatment Failure

Antoine Beauvais

Poster

Abstract

Lowering of Mean Pulmonary Arterial Pressure is a Prognostic Marker in Pulmonary Hypertension Patients treated with Subcutaneous Treprostinil

Roela Sadushi-kolici

Poster

Abstract

Health related quality of life in pulmonary arterial hypertension in the US, Europe and Japan

Rogier Klok

Poster

Abstract

Comparison between REVEAL Lite 2.0 and COMPERA 2.0 for risk stratification in Pulmonary Arterial Hypertension

Sandeep Sahay

Poster

Abstract

Role of 6-MWT and NT-proBNP in the evaluation of survival in Pulmonary Arterial Hypertension

Chiara Milano

Poster

Abstract

Capillary NT-proBNP is a valid tool for remote risk assessment in pulmonary hypertension.

Harrison Stubbs

Poster

Abstract

Identification of novel biomarkers for use in clinical trials in BMPRII pulmonary hypertension

Rowena Jones

Poster

Abstract

A patient preference study in pulmonary arterial hypertension (PAH): what matters most?

Wenjing Li

Poster

Abstract

Vasoreactivity in combined pre- and post-capillary pulmonary hypertension and survival

Eileen Harder

Poster

Abstract

The ERS International Congress 2023, Milan

#{title}